Decreased ESS score post-RADA16. Change in ESS, represented on the individual patient (A) and cohort (B) level. Baseline ESS of 5.0 (SD, 1.6) decreased by a mean of 2.0 (SD, 1.6) to an ESS of 3.0 (SD, 1.6) at a mean duration of 46.9 days after treatment.